Research at FAST

49 Representative Publications • Leung HW, .., Lee TK . NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. Cancer Lett. 2020 , 476:48-56 • Leung CO, .., Lee TK . Overriding adaptive resistance in sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma. Hepatology 2019 ; doi: 10.1002/hep.30989 • Luk ST, .., Lee TK , Ma S. Deficiency in embryonic stem cell marker REX1 activates MKK6-dependent p38 MAPK signaling to drive hepatocarcinogenesis. Hepatology 2019 ; doi: 10.1002/hep.31020 • Cheng BY, .., Lee TK . IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res. 2018 , 78:2332-42 • Ma MKF, .., Lee TK . Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J. Hepatol. 2017 , 67:979-90 • Lau EY, .., Lee TK . Cancer-associated fibroblasts regulate tumor initiating cell plasticity in hepatocellular carcinoma through c-Met /FRA /HEY1 signaling. Cell Rep 2016 , 15:1175-89 • Lo J, .., Lee TK . Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology 2015 , 62: 534-45 • Lee TK , ..., Ng IO. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014 , 60:179-91 • Lee TK , ..., Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3- mediated NANOG regulation. Cell Stem Cell 2011 , 9:50-63 Awards and Achievements • Faculty Outstanding Research Output Award, Faculty of Medicine, HKU ( 2011 , 2012 & 2018 ) • Young Researcher Cancer Development Scheme (YRCDS), State Key Laboratory for Liver Research ( 2011 ) Patents • “The use of HCN inhibitors for treatment of cancers” (Co-I)(PCT/16/607,035) • “Combination use of CD47 antibodies/inhibitors with sorafenib for treatment of liver cancer” (US patent US20170071918) ( 2017 ) Dr LEE Kin Wah Terence Associate Professor Research Areas Liver cancer stem cells; Tumor microenvironment; Therapeutic targeting of HCC Qualification BSc (HKUST) MPhil (HKU) PhD (HKU) ORCID ID 0000-0003-0682-322X Department of Applied Biology & Chemical Technology Department of Applied Biology & Chemical Technology